Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study

Type of publication: Academic publication
Disease: Neuromuscular disease

Authors:

Johan Lim, Filip Eftimov, Camiel Verhamme, Esther Brusse, Jessica E Hoogendijk, Christiaan G J Saris, Joost Raaphorst, Rob J De Haan, Ivo N van Schaik, Eleonora Aronica, Marianne de Visser, Anneke J van der Kooi


Objectives.
We explored efficacy and safety of IVIg as first-line treatment in patients with an idiopathic inflammatory myopathy.

Methods.
In this investigator-initiated phase 2 open-label study, we included 20 adults with a newly diagnosed,
biopsy-proven idiopathic inflammatory myopathy, and a disease duration of less than 9 months. Patients with IBM
and prior use of immunosuppressants were excluded. The standard treatment regimen consisted of IVIg (Privigen)
monotherapy for 9 weeks: a loading dose (2 g/kg body weight) and two subsequent maintenance doses (1 g/kg
body weight) with a 3-week interval. The primary outcome was the number of patients with at least moderate improvement on the 2016 ACR/EULAR Total Improvement Score. Secondary outcomes included time to improvement,
the number of patients requiring rescue medication and serious adverse events.

Results.
We included patients with DM (n ¼ 9), immune-mediated necrotizing myopathy (n ¼ 6), non-specific myositis/overlap myositis (n ¼ 4) and anti-synthetase syndrome (n ¼ 1). One patient was excluded from analyses because of minimal weakness resulting in a ceiling effect. Eight patients (8/19 ¼ 42.0%; Clopper–Pearson 95% CI:
19.6, 64.6) had at least moderate improvement by 9 weeks. Of these, six reached improvement by 3 weeks. Seven
patients required rescue medication due to insufficient efficacy and prematurely ended the study. Three serious adverse events occurred, of which one was pulmonary embolism.

Conclusion.
First-line IVIg monotherapy led to at least moderate improvement in nearly half of patients with a
fast clinical response in the majority of responders.


Published: 25 October 2020
Journal: Rheumatology, volume keaa459

Link: doi.org/10.1093/rheumatology/keaa459

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern